ENTRY       D10773                      Drug
NAME        Atezolizumab (USAN/INN);
            Atezolizumab (genetical recombination) (JAN);
            Tecentriq (TN)
PRODUCT     TECENTRIQ (Genentech)
FORMULA     C6446H9902N1706O1998S42
EXACT_MASS  144521.3941
MOL_WEIGHT  144610.5555
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS DSWIHWVRQA PGKGLEWVAW ISPYGGSTYY
            ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARRH WPGGFDYWGQ GTLVTVSSAS
            TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYAST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
            GNVFSCSVMH EALHNHYTQK SLSLSPGK
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YLYHPATFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H145-H201, H221-L214, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'214, H'262-H'322, H'368-H'426, L23-L88, L134-L194, L'23-L'88, L'138-L'194)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FF05
            Product: D10773<JP/US>
EFFICACY    Antineoplastic, Immune checkpoint inhibitor, Anti-PD-L1 antibody
  DISEASE   Urothelial carcinoma [DS:H00022]
            Urothelial carcinoma (PD-L1 expressed) [DS:H00022]
            Non-small cell lung cancer [DS:H00014]
            Breast cancer (PD-L1 expressed, HR negative, HER2 negative) [DS:H00031]
            Small cell lung cancer [DS:H00013]
            Hepatocellular carcinoma [DS:H00048]
  TYPE      Monoclonal antibody
TARGET      PDL1 (CD274) [HSA:29126] [KO:K06745]
  PATHWAY   hsa04514(29126)  Cell adhesion molecules
            hsa05235(29126)  PD-L1 expression and PD-1 checkpoint pathway in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
                 L01FF05 Atezolizumab
                  D10773  Atezolizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Atezolizumab
                D10773  Atezolizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10773  Atezolizumab (USAN/INN); Atezolizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10773  Atezolizumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10773  Atezolizumab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                PDL1 (CD274)
                 D10773  Atezolizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10773
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10773
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10773
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10773
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10773
DBLINKS     CAS: 1380723-44-3
            PubChem: 312642102
///
